Effectiveness Of Daclatasvir-Based Regimens In Patients With Chronic Hepatitis C Infection In Europe: Experience From Named Patient Program And From Early Post-Marketing Authorization Period

Trial Profile

Effectiveness Of Daclatasvir-Based Regimens In Patients With Chronic Hepatitis C Infection In Europe: Experience From Named Patient Program And From Early Post-Marketing Authorization Period

Completed
Phase of Trial: Phase IV

Latest Information Update: 11 May 2016

At a glance

  • Drugs Daclatasvir (Primary) ; Ribavirin; Simeprevir; Sofosbuvir
  • Indications Hepatitis C
  • Focus Therapeutic Use
  • Sponsors Bristol-Myers Squibb
  • Most Recent Events

    • 03 May 2016 Status changed from active, no longer recruiting to completed.
    • 17 Apr 2016 Results of the sustained virologic response at 12 weeks post treatment (n=226) presented at The International Liver Congress 2016.
    • 08 Feb 2016 Planned End Date changed from 1 Jan 2016 to 1 Feb 2016, as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top